297 related articles for article (PubMed ID: 14744949)
1. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949
[TBL] [Abstract][Full Text] [Related]
2. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
3. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X
Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407
[TBL] [Abstract][Full Text] [Related]
4. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Shen L; Fitzloff JF; Cook CS
Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.
Tracy TS; Korzekwa KR; Gonzalez FJ; Wainer IW
Br J Clin Pharmacol; 1999 May; 47(5):545-52. PubMed ID: 10336579
[TBL] [Abstract][Full Text] [Related]
6. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
Kim HJ; Choi JS
Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
[TBL] [Abstract][Full Text] [Related]
7. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Hu N; Xie S; Liu L; Wang X; Pan X; Chen G; Zhang L; Liu H; Liu X; Liu X; Xie L; Wang G
Drug Metab Dispos; 2011 Mar; 39(3):419-25. PubMed ID: 21135265
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
9. Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity.
Krasulova K; Holas O; Anzenbacher P
Molecules; 2017 Nov; 22(11):. PubMed ID: 29099769
[TBL] [Abstract][Full Text] [Related]
10. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
11. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
[TBL] [Abstract][Full Text] [Related]
12. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.
Yeo KR; Yeo WW
Br J Clin Pharmacol; 2001 May; 51(5):461-70. PubMed ID: 11422004
[TBL] [Abstract][Full Text] [Related]
14. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats.
Xie SS; Hu N; Jing XY; Liu XD; Xie L; Wang GJ; Liu CH
J Pharm Pharmacol; 2010 Apr; 62(4):440-7. PubMed ID: 20604832
[TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
16. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.
Sandström R; Knutson TW; Knutson L; Jansson B; Lennernäs H
Br J Clin Pharmacol; 1999 Aug; 48(2):180-9. PubMed ID: 10417494
[TBL] [Abstract][Full Text] [Related]
17. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi DH; Chung JH; Choi JS
Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
Chung JH; Choi DH; Choi JS
Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
